A detailed history of Buckingham Strategic Partners transactions in Biogen Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 1,116 shares of BIIB stock, worth $210,622. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,116
Previous 964 15.77%
Holding current value
$210,622
Previous $207,000 24.64%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $28,959 - $35,981
152 Added 15.77%
1,116 $258,000
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $204,387 - $258,072
964 New
964 $207,000
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $231,992 - $281,875
-919 Reduced 54.83%
757 $209,000
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $326,300 - $449,938
1,676 New
1,676 $448,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $27.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Buckingham Strategic Partners Portfolio

Follow Buckingham Strategic Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.